GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

Biotech dealmaking is accelerating as companies move to address looming patent cliffs, benefit from newly buoyant public markets, and strengthen drug pipelines. The article frames the transaction as part of a broader sector-wide M&A surge rather than a company-specific earnings event.

Analysis

Biotech dealmaking is accelerating as companies move to address looming patent cliffs, benefit from newly buoyant public markets, and strengthen drug pipelines. The article frames the transaction as part of a broader sector-wide M&A surge rather than a company-specific earnings event.